Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma

Children's Oncology Group

Status

Completed

Conditions

Lymphoma

Treatments

Genetic: microarray analysis

Other: laboratory biomarker analysis

Other: mass spectrometry

Other: immunohistochemistry staining method

Genetic: western blotting

Genetic: protein expression analysis

Other: flow cytometry

Study type

Observational

Funder types

NETWORK

NIH

Identifiers

NCT01366170

COG-ANHL11B1 (Other Identifier)

NCI-2011-02860 (Registry Identifier)

ANHL11B1 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment.

PURPOSE: This research trial studies biomarker expression in tissue samples from young patients with anaplastic large cell lymphoma.

Full description

OBJECTIVES:

To determine the expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in anaplastic large cell lymphoma (ALCL).
To correlate the expression of these proteins with the levels of anaplastic lymphoma kinase (ALK) autoantibodies in patient of ANHL0131.

OUTLINE: Archived tissue microarray samples are analyzed by mass spectrometry and validated by Western blotting, flow cytometry, and IHC.

Enrollment

7 estimated patients

Sex

All

Ages

Under 20 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS: